Boston Scientific director awarded 24 restricted shares

Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/04/2026 - 07:35 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Susan E. Morano received an equity grant of 24 shares of common stock on March 2, 2026, at no cash cost to her. The award is restricted stock granted in lieu of 50% of her cash compensation, valued at $1,845.25 based on the closing share price on the grant date, and will vest in full at the next annual meeting of stockholders. Following this grant, she directly holds 6,663 Boston Scientific shares.

Insider Trade Summary

Grant/Award: 24 shares

Grant/Award 1 txn

Insider Morano Susan E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24	$0.00	$0.00

Holdings After Transaction: Common Stock — 6,663 shares (Direct)

Holdings Before and After: Common Stock, 6,639 to 6,663 shares (Direct)

Footnotes (1)

1. F1. Restricted stock granted in lieu of 50% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $1,845.25, divided by the closing price of common stock on the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Boston Scientific (BSX) report for Susan E. Morano?

Boston Scientific reported that director Susan E. Morano received a grant of 24 shares of common stock on March 2, 2026. This was a restricted stock award rather than an open-market purchase, linked to her director compensation structure.

Was the March 2, 2026 Boston Scientific (BSX) insider transaction a stock purchase or an award?

The March 2, 2026 transaction for Susan E. Morano was a grant or award of restricted stock, not an open-market purchase. It reflects equity compensation issued at no cash cost to her, in lieu of a portion of her normal cash compensation as director.

How many Boston Scientific (BSX) shares did Susan E. Morano hold after the latest grant?

After receiving the 24-share restricted stock grant, Susan E. Morano directly held a total of 6,663 Boston Scientific common shares. This figure reflects her ownership immediately following the March 2, 2026 equity compensation transaction reported in the Form 4 filing.

What was the value of Susan E. Morano’s Boston Scientific (BSX) restricted stock grant?

The restricted stock granted to Susan E. Morano was valued at $1,845.25 in total. This value was calculated by dividing $1,845.25 by the closing price of Boston Scientific common stock on the March 2, 2026 grant date, determining the 24-share award size.

How is Susan E. Morano’s Boston Scientific (BSX) director compensation structured in this grant?

For this transaction, 50% of Susan E. Morano’s cash compensation as a Boston Scientific director was replaced with restricted stock. She received 24 shares valued at $1,845.25, aligning part of her compensation with equity that vests at the next annual stockholders’ meeting.

When do Susan E. Morano’s newly granted Boston Scientific (BSX) shares vest?

The 24 restricted shares granted to Susan E. Morano vest in full upon the next annual meeting of Boston Scientific stockholders. Until that vesting date, the shares are subject to restrictions typical of equity compensation granted to company directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morano Susan E

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MA 01752-1234

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		24(1)	A	$0.0000	6,663	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock granted in lieu of 50% of cash compensation, vesting in full upon the next annual meeting of stockholders. Reflects a value of $1,845.25, divided by the closing price of common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.